Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab in COVID-19 Complications
NCT04475588Phase 2Completed
- Sponsor
- Biocon
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of itolizumab in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), cytokine release syndrome (CRS), sponsored by Biocon. Started May 2020; status: completed.
02
Drugs
itolizumab
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04475588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475588.